Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

Diabetes

Volumn 53, Issue 9, 2004, Pages 2397-2403

  Degn, Kristine B ^a   Brock, Birgitte ^a   Juhl, Claus B ^a   Djurhuus, Christian B ^a   Grubert, Jaime ^b   Kim, Dennis ^b   Han, Jenny ^b   Taylor, Kristin ^b   Fineman, Mark ^b   Schmitz, Ole ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; COUNTERREGULATORY HORMONE; EXENDIN 4; GLUCAGON; GLUCOSE; GROWTH HORMONE; HORMONE; HYDROCORTISONE; INSULIN; NORADRENALIN; PLACEBO; SYNTHETIC EXENDIN 4; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CONCENTRATION TIME CURVE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE DEPENDENT INSULIN RELEASE; HEADACHE; HORMONAL COUNTERREGULATION; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; HYPERINSULINEMIA; HYPERINSULINEMIC HYPOGLYCEMIC CLAMP TECHNIQUE; HYPOGLYCEMIA; INSULIN INFUSION; INSULIN RELEASE; INSULIN SECRETORY RATE; MALE; METHODOLOGY; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIPLE BLIND PROCEDURE;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; FATTY ACIDS, NONESTERIFIED; GLUCAGON; HUMANS; HYDROCORTISONE; HYPOGLYCEMIA; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; PEPTIDES; VENOMS;

EID: 4344713643     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.9.2397     Document Type: Article

References (31)

1. Kahn SE, Porte D Jr: Pathophysiology of type II diabetes mellitus. In Diabetes Mellitus. 5th ed. Porte D Jr, Sherwin RS, Eds. Stamford, CT, Appleton & Lange, 1985, p. 487-512
2. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
3. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA: Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059, 2000
4. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723, 2001
5. UK Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
6. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
7. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999
8. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 22:403-408, 1999
9. Drucker DJ: Glucagon-like peptides. Diabetes 47:159-169, 1998
10. Nielsen LL, Young AA, Parkes DG: Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117:77-88, 2004
11. Young AA: Glucagon-like peptide-1, exendin and insulin sensitivity. In Insulin Resistance and Insulin Resistance Syndrome. Hansen B, Shafrir E, Eds. New York, Harwood Academic Press, 2002, p. 235-262
12. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268:19650-19655, 1993
13. Nielsen LL, Baron AD: Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 4:401-405, 2003
14. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370-2377, 2003
15. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082-3089, 2003
16. Taylor K, Poon T, Nielsen L, Cole L, Han J, Varns A, Kin D, Baron, A, Fineman M, Kolterman O: Effects of exenatide (synthetic exendin-4) on glucose control and safety in patients with type 2 diabetes treated with metformin, a sulfonylurea, or both: an ongoing, open-label phase 3 trial (Abstract). Diabetes Metab 29:4S265, 2003
17. Nyholm B, Moller N, Gravholt CH, Orskov L, Mengel A, Bryan G, Moyses C, Alberti KG, Schmitz O: Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:1083-1089, 1996
18. Hussain MA, Schmitz O, Christiansen JS, Christensen NJ, Alberti KG, Froesch ER: IGF-I alters skeletal muscle substrate metabolism and blunts recovery from insulin-induced hypoglycemia. Am J Physiol 270:E545-E551, 1996
19. Carstensen E, Yudkin JS: Platelet catecholamine concentrations after short-term stress in normal subjects. Clin Sci (Lond) 86:35-41, 1994
20. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank B: Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 77:98-105, 1986
21. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH: Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87:1239-1246, 2002
22. Davis SN, Goldstein RE, Jacobs J, Price L, Wolfe R, Cherrington AD: The effects of differing insulin levels on the hormonal and metabolic response to equivalent hypoglycemia in normal humans. Diabetes 42:263-272, 1993
23. Nauck MA, El-Ouaghlidi A, Hompesch M, Jacobson J, Bodil E: No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2-diabetes (Abstract). Diabetes 52 (Suppl. 1):A128, 2003
24. Beak SA, Small CJ, Ilovaiskaia I, Hurley JD, Ghatei MA, Bloom SR, Smith DM: Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells. Endocrinol 137:4130-4138, 1996
25. Beak SA, Heath MM, Small CJ, Morgan DG, Ghatei MA, Taylor AD, Buckingham JC, Bloom SR, Smith DM: Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line. J Clin Invest 101:1334-1341, 1998
26. Djurhuus CB, Hansen TK, Gravholt C, Orskov L, Hosoda H, Kangawa K, Jorgensen JO, Holst JJ, Schmitz O: Circulating levels of ghrelin and GLP-1 are inversely related during glucose ingestion. Horm Metab Res 34:411-413, 2002
27. Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk FW, Holst JJ, Rizza RA: Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes. Diabetes 50:565-572, 2001
28. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA: Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 45:1410-1415, 2002
29. Rizza R, Verdonk C, Miles J, Service FJ, Gerich J: Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man. J Clin Invest 63:1119-1123, 1979
30. Shamoon H, Friedman S, Canton C, Zacharowicz L, Hu M, Rossetti L: Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus. J Clin Invest 93:2562-2571, 1994
31. Bolli GB, Tsalikian E, Haymond MW, Cryer PE, Gerich JE: Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus: paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions. J Clin Invest 73:1532-1541, 1984